Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | VP, Human Resources | December 31, 2009 | January 05, 2010 |
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 10,284 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 10,284 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
| Common stockSEC Table I · non-derivative | IndirectBy Foster Family Revocable Trust | 2,200 |
Reported balance
Holding disclosure · report date 2026-06-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,200 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
JOHNSON & JOHNSON
Report date December 31, 2009 · Filed January 05, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | IndirectJohnson & Johnson Stock Fund under the 401(k) Savings Plan | 1,181 |
Reported balance
After 2009-12-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2009-12-31 · Other · Acquired 34 · Balance 1,181 F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,998 |
Reported balance
After 2009-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-12-31 · Grant · Acquired 45 · Balance 5,998 F4: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. |
| Common StockSEC Table I · non-derivative | Direct | 4,583 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,583 F1: Includes 819 shares held under Issuer's Dividend Reinvestment Program. |
| CommonSEC Table I · non-derivative | IndirectESOP under the 401(k) Savings Plan | 33 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 33 F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 819 shares held under Issuer's Dividend Reinvestment Program.
F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009).
F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009).
F4: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001628280-26-041566 · wk-form4_1780949818.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 8 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $7.68 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 7 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 39,062 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 6 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 39,062 | Not disclosed Strike: $14.83 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 9,006 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,006 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 9,006 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 13,510 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,510 Underlying: Common Stock · 13,510 shares Expires 2032-01-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 13,510 | Not disclosed Strike: $10.92 | Not disclosed |
DisclosureSEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,510 shares Expires 2032-01-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000057 · wk-form4_1750710263.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000057 · wk-form4_1750710263.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 15,768 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001439222-25-000057 · wk-form4_1750710263.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000057 · wk-form4_1750710263.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,816 Underlying: Common stock · 2,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 22:13 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001628280-25-029770 · wk-form4_1749161364.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 11,774 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001439222-24-000105 · wk-form4_1719259804.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000105 · wk-form4_1719259804.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000091 · wk-form4_1718659962.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GiftCommon stock | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000091 · wk-form4_1718659962.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,348 F1 · kind: This disposition reflects a gift of 3,564 shares to a not-for-profit organization. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000091 · wk-form4_1718659962.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:58 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001894562-24-000037 · wk-form4_1718398728.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,285 | $31.62 | $40,631.70 |
DisclosureSEC source: 0001439222-24-000061 · wk-form4_1710187757.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,524 Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:49 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,415 | $31.99 | $141,235.85 |
DisclosureSEC source: 0001439222-24-000058 · wk-form4_1709855334.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $31.99 to $32.04. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:49 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 300 | $32.21 | $9,663.00 |
DisclosureSEC source: 0001439222-24-000058 · wk-form4_1709855334.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,224 Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 25,000 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-23-000125 · wk-form4_1691784273.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,307 Underlying: Common stock · 25,000 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 25,000 | $25.96 | $648,887.50 |
DisclosureSEC source: 0001439222-23-000125 · wk-form4_1691784273.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,524 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $25.69 to $26.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 25,000 | $18.09 | $452,250.00 |
DisclosureSEC source: 0001439222-23-000125 · wk-form4_1691784273.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:38 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000097 · wk-form4_1687552715.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:38 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000097 · wk-form4_1687552715.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:49 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 39,062 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001894562-23-000026 · wf-form4_168695217738921.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 14, 2024 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 18,958 | $0.00 Strike: $26.56 | $0.00 |
DisclosureSEC source: 0001439222-23-000073 · wk-form4_1686860412.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,958 Underlying: Common stock · 18,958 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000073 · wk-form4_1686860412.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,388 Underlying: Common stock · 3,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GiftCommon stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000006 · wf-form4_167407612959834.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,549 Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:31 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 9,006 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-22-026823 · wf-form4_166638424668882.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,006 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · derivative.exercise_date: The shares underlying this option shall vest in three equal annual installments beginning on September 13, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 29,307 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-22-000062 · wf-form4_165601498762477.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 Underlying: Common stock · 29,307 shares Expires 2032-06-21 F3 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000062 · wf-form4_165601498762477.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Underlying: Common stock · 4,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000048 · wf-form4_165342301824518.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000048 · wf-form4_165342301824518.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000053 · wf-form4_162266448299578.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000053 · wf-form4_162266448299578.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,888 | $0.00 Strike: $56.76 | $0.00 |
DisclosureSEC source: 0001439222-21-000045 · wf-form4_162188908499200.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common stock · 8,888 shares Expires 2031-05-20 F3 · derivative.exercise_date: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000045 · wf-form4_162188908499200.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 Underlying: Common stock · 1,585 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000052 · wf-form4_159104599634402.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000052 · wf-form4_159104599634402.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000052 · wf-form4_159104599634402.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686 Underlying: Common stock · 1,686 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,096 | $0.00 Strike: $53.35 | $0.00 |
DisclosureSEC source: 0001439222-20-000052 · wf-form4_159104599634402.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 Underlying: Common stock · 8,096 shares Expires 2030-05-28 F2 · derivative.exercise_date: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033618 · doc4.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.